New drug aims to tame rare bleeding disorder
NCT ID NCT06659640
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This study tests a new medicine called ALN-6400 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The trial first checks safety in healthy volunteers, then tests how well the drug controls symptoms in HHT patients. It is a phase 1/2 study, meaning it is early-stage research focused on safety and initial effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGBirmingham, Alabama, 35233, United States
-
Clinical Trial Site
RECRUITINGCypress, California, 90630, United States
-
Clinical Trial Site
RECRUITINGGainesville, Florida, 32608, United States
-
Clinical Trial Site
RECRUITINGIndianapolis, Indiana, 46260, United States
-
Clinical Trial Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Clinical Trial Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Clinical Trial Site
RECRUITINGSt Louis, Missouri, 63110, United States
-
Clinical Trial Site
RECRUITINGChapel Hill, North Carolina, 27514, United States
-
Clinical Trial Site
RECRUITINGCamperdown, 2050, Australia
-
Clinical Trial Site
RECRUITINGParkville, 3050, Australia
-
Clinical Trial Site
RECRUITINGMount Royal, H3P 3P1, Canada
-
Clinical Trial Site
RECRUITINGToronto, M5B 1W8, Canada
-
Clinical Trial Site
RECRUITINGBordeaux, 33000, France
-
Clinical Trial Site
RECRUITINGBron, 69500, France
-
Clinical Trial Site
RECRUITINGHomburg, 66421, Germany
-
Clinical Trial Site
RECRUITINGL'Hospitalet de Llobregat, 8907, Spain
Conditions
Explore the condition pages connected to this study.